Business
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
GENEVA, September 08, 2025--Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
About this update from Alcon Ag
GENEVA, September 08, 2025 --( BUSINESS WIRE )--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will present compelling scientific data at the 43 rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Copenhagen, Denmark from 12-15 September. During the meeting, Alcon will showcase groundbreaking cataract, refractive and glaucoma technologies at booth C2.033. More than 40 studies will also be presented at the meeting, demonstrating the benefits of Alcon technologies. In addition, Alcon will host a number of symposia and activities, which are detailed at MyAlcon.com . Launching bold innovation in Europe At this year’s event, Alcon will highlight its latest innovations that are available in Europe, including: *Based on bench testing. †Compared to CENTURION and CONSTELLATION Vision Systems. Based on bench data. **Based on worldwide unit sales of AcrySof ® IQ Vivity and Clareon Vivity IOLs, as of Q4, 2024. "As ophthalmic practices face rising procedural volumes and increasing pressure to deliver both precision and efficiency, Alcon remains committed to providing integrated solutions that elevate every stage of the surgical journey," said Sunil Vasanth, Vice President Surgical, Alcon Europe. "With the launch of UNITY VCS, the completion of our Clareon IOL portfolio, and a growing body of clinical evidence to support their use, we’re empowering surgeons with a comprehensive, connected platform designed to streamline workflows and deliver exceptional outcomes for patients across a broad range of needs." 1-5,16,17,23-25 Announcing exceptional outcomes data with Alcon’s industry-leading surgical portfolio Alcon will present more than 40 studies over the course of the meeting, demonstrating the benefits of operating with Alcon technologies across cataract, refractive, vitreoretinal and glaucoma procedures. Researchers have extensively studied the Vivity EDOF IOL in populations with different co-morbidities, including some that were not previously considered candidates for a presbyopia-correcting IOL. New results being presented at ESCRS add to its robust body of evidence of more than 10 clinical studies in 700+ patients demonstrating positive outcomes and/or patient satisfaction following Vivity IOL implantations in special populations , including: New data will be presented on UNITY VCS as well as studies highlighting the benefits of operating at more physiologic IOP , including reduced breakthrough pain medication use. Data presentations include: In addition, Alcon Global Medical Affairs will host a symposium on "Optimizing cataract surgery: Focus on real-world experience with near physiologic IOP," with Moderator Gábor Scharioth (Germany), and faculty members David Lockington (UK), Cristina Peris-Martinez (Spain) and Matthew Rauen (US) on Saturday, 13 Sep, 16:15 - 17:15 CEST, in Auditorium 10 . In refractive, Alcon will present wavelight plus head-to-head data, revealing better outcomes versus more commonly used technologies : In addition to launching innovations and presenting excellent outcomes data, Alcon will host several activities at ESCRS—including additional symposium sessions highlighting UNITY VCS|CS and Advanced Technology IOLs as well as live surgery presentations showcasing Hydrus ® Microstent and Clareon Vivity IOL, and Voyager DSLT. For more information about Alcon’s participation at ESCRS 2025, visit Alcon Booth #C2.033 on the conference floor, or see the complete schedule of events at MyAlcon.com . Further scientific content from Alcon can be found at AlconScience.com . Alcon medical device(s) comply with the current legislation for the medical devices. Please refer to relevant products directions for use or operator’s manuals for complete lists of indications, contraindications and warnings. Products mentioned may not be approved in all markets; please reach out to your Alcon Representative for questions about availability in your local market. This content is intended for Healthcare Professionals (HCPs) only. Please note that product-related promotion of Medical Devices to non-HCPs may be subject to restrictions based on local rules and regulations. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com . References All ESCRS Abstracts can be accessed here: Abstracts-ESCRS-2025.xlsx *Based on bench testing. †Compared to CENTURION and CONSTELLATION Vision Systems. Based on bench data. **Based on worldwide unit sales of AcrySof ® IQ Vivity and Clareon Vivity IOLs, as of Q4, 2024. Connect with us on Facebook LinkedIn View source version on businesswire.com: https://www.businesswire.com/news/home/20250905203435/en/ Contacts Investor Relations Allen Trang + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth) [email protected] Media Relations Cara Jones-Faye + 41 79 93 3811 (Geneva) [email protected] Melanie McCoy + 1 682 304 8657 (Fort Worth) [email protected]